Prostate cell lines
US7303911B2 · kind B2 · utility
0Cited by
0References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 30, 2001 |
| Grant date | Dec 4, 2007 |
| Priority date | — |
| Expiry date | Mar 14, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/5152
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An increasingly aged population and better diagnosis has lead to an apparent increase in the prevalence of prostate cancer in men. There is an acute need to better understand the progression of this disease from its locally confined site of initiation to the end stage widely metastatic disease with attendant morbidity and mortality, It has historically been difficult to raise and maintain immortalized prostate cell lines in culture. We have derived a cell line selected from the group consisting of clones ONYCAP 1 and ONYCAP23. The cell lines are characterized as being prostate epithelial in origin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.